Ignite Creation Date:
2024-07-17 @ 11:58 AM
Last Modification Date:
2024-10-26 @ 3:33 PM
Study NCT ID:
NCT06474169
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-06-27
First Post:
2024-06-10
Brief Title:
Assessment of T-cell Response and In-vitro Proof-of-concept of T-cell Engineering in Chronic ESKD Patients
Sponsor:
Centre Hospitalier Régional dOrléans
Organization:
Centre Hospitalier Régional dOrléans
Study Overview
Official Title:
Assessment of T-cell Response and In-vitro Proof-of-concept of T-cell Engineering in Chronic End-stage Kidney Disease Patients
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
LYMPHOVIRCT
Brief Summary:
This is a comparative prospective non-interventional study to evaluate immune response in patients with chronic kidney disease The primary objective is to define immunodeficiency phenotype and function of T cells in patients with end-stage kidney disease The second objective is to provide an in-vitro proof-of-concept of T-cell engineering in the context of end-stage kidney disease
The study population was patients with chronic kidney disease
The study population was patients with chronic kidney disease
Detailed Description:
The development of chronic kidney disease CKD and its progression to this terminal stage end-stage kidney disease ESKD remains a significant source of reduced quality of life and premature mortality ESKD represents the complete and definitive alteration of renal function requiring the use of renal replacement therapy dialysis or kidney transplantation
ESKD is associated with a significant increase in mortality with a death rate of 109 and a median age of 77 years Thus the average survival of patients with ESKD is lower than that of the general population Among the causes of death in ESKD infectious diseases represent the 2nd cause of mortality and are responsible for 15 to 20 of deaths The occurrence of complications increases with the decline of renal function although individual risk remains poorly characterized Thus after infection ESKD patients are at increased risk of complications hospitalization and death This susceptibility to infections is explained by a complex alteration of the immune system including a pro-inflammatory state and immunodeficiency However this immunodeficiency is still partially understood Premature-aged T cells were found with a decrease in naive T cells and an increase in memory T cells suggesting a more advanced T-cell differentiation than in the population of the same age
The study aims to describe immunodeficiency in patients with ESKD in order to better assess the infection risk for each patient particularly in patients awaiting kidney transplantation
This is a comparative prospective non-interventional study Three groups of participants will be included 1 patients with ESRK 2 patients with stage 3 CKD and 3 healthy donors Participants will be included after being informed and after obtaining no opposition to participate Immunodeficiency in patients with chronic kidney disease will be performed from a single blood sample
A total of 100 participants will be included in this study based on the detection probability of naïve T cells 45 in patients with stage 3 CKD and healthy donors vs 10-15 in ESKD patients and considered a power of 80 and an alpha risk of 5
The development of blood tests to evaluate the antiviral immune response could allow for the definition of new milestones for the development of future treatments or diagnostics for these diseases
ESKD is associated with a significant increase in mortality with a death rate of 109 and a median age of 77 years Thus the average survival of patients with ESKD is lower than that of the general population Among the causes of death in ESKD infectious diseases represent the 2nd cause of mortality and are responsible for 15 to 20 of deaths The occurrence of complications increases with the decline of renal function although individual risk remains poorly characterized Thus after infection ESKD patients are at increased risk of complications hospitalization and death This susceptibility to infections is explained by a complex alteration of the immune system including a pro-inflammatory state and immunodeficiency However this immunodeficiency is still partially understood Premature-aged T cells were found with a decrease in naive T cells and an increase in memory T cells suggesting a more advanced T-cell differentiation than in the population of the same age
The study aims to describe immunodeficiency in patients with ESKD in order to better assess the infection risk for each patient particularly in patients awaiting kidney transplantation
This is a comparative prospective non-interventional study Three groups of participants will be included 1 patients with ESRK 2 patients with stage 3 CKD and 3 healthy donors Participants will be included after being informed and after obtaining no opposition to participate Immunodeficiency in patients with chronic kidney disease will be performed from a single blood sample
A total of 100 participants will be included in this study based on the detection probability of naïve T cells 45 in patients with stage 3 CKD and healthy donors vs 10-15 in ESKD patients and considered a power of 80 and an alpha risk of 5
The development of blood tests to evaluate the antiviral immune response could allow for the definition of new milestones for the development of future treatments or diagnostics for these diseases
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None